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SUMMARY
T790M in epidermal growth factor receptor (EGFR) 
accounts for about 50% of the acquired resistance to EGFR 
tyrosine kinase inhibitor (TKI) in patients with non–small-
cell lung cancer (NSCLC) carrying sensitive EGFR muta-
tions. Earlier studies suggested that T790M mutation was 
also detected in about 2% of TKI-naive NSCLCs. Recently, 
three groups reported that, by using highly sensitive assays, 
T790M mutation was detected in about 40% of TKI-naive 
NSCLCs with sensitive EGFR mutations. When we care-
fully studied these reports, we realized that all of those 
data were generated from formalin-fixed paraffin-embed-
ded (FFPE) tumor tissue samples, which raised a concern 
that the high mutation positivity could be consequence of 
formalin fixation. To address this, we assessed the T790M 
mutation in 36 pairs of frozen and FFPE tumor tissues of 
TKI-naive NSCLCs with sensitive EGFR mutations, using 
an enzyme-based mutant-enriched polymerase chain reac-
tion assay (ME-PCR) with 0.1% sensitivity. In addition, 
frozen and FFPE adjacent normal tissues from the same 
patients were also assessed for a further comparison. 
Although 41.7% (15 of 36) of the T790M-positive rate was 
detected in the tumor FFPE samples, which was consistent 
with previous reports, only one of the 36 frozen counter-
parts (2.8%) was T790M positive. As suspected, 48.5% 
(16 of 33) of T790M mutation rates was also identified in 
FFPE adjacent normal tissues but none of the 35 frozen 
adjacent normal tissues was T790M positive. Our results 
indicate that the high T790M positivity detected in TKI-
naive NSCLC, using some highly sensitive methods, may 
in some cases be FFPE-derived artifacts.
Activating mutations in EGFR gene confer dramatic 
sensitivity to EGFR TKIs.1 However, most patients under-
went relapse within 1 year after the initiation of TKI treat-
ment.2 T790M, a secondary mutation in EGFR gene, has been 
identified as the major mechanism of the acquired EGFR-
TKI resistance, accounting for about 50% of TKI-relapsed 
NSCLCs.3–8 However, it is unknown how T790M arises in 
tumor cells. Conventional DNA sequencing revealed that 
about 2% T790M preexists with sensitive EGFR mutations 
in TKI-naive NSCLCs.9,10 It is not clear whether the majority 
of the T790M mutation in TKI-relapsed NSCLCs is acquired 
during disease progression or emerges from the preexisting 
T790M in TKI-naive patients as a minor population but unde-
tectable by conventional sequencing. More sensitive assays 
capable of detecting low frequency of T790M are emerg-
ing to address this question. With recent progress made in 
the development of second-generation EGFR TKIs targeting 
tumors harboring T790M mutation,11 it is critical to accurately 
identify the T790M-positive NSCLC patients, which will help 
guide the patient selection in clinical trials and treatments. 
Although rebiopsied tumor tissues are ideal for detection of 
TKI-resistant T790M, which is challenging in clinical prac-
tice, it would be valuable to understand T790M baseline in 
TKI-naive patients and whether it could be used to predict the 
T790M status in TKI-relapsed patients.
With the emerging highly sensitive techniques, about 
40% of T790M has been identified in TKI-naïve NSCLCs in 
some studies,12–14 which is much higher than the T790M rate 
detected by conventional methods.9,10 The study by Su et al.13 
recently published in J Clin Oncol used matrix-assisted laser 
desorption ionization–time of flight mass spectrometry (1.5% 
sensitivity) to evaluate T790M mutation in NSCLCs and used 
next-generation sequencing (3.7% sensitivity) to attempt to 
validate the results. Matrix-assisted laser desorption ioniza-
tion–time of flight mass spectrometry identified 41% (23 of 
56) of T790M rate in pre-TKI NSCLCs carrying sensitive 
EGFR mutations. In addition, Rosell et al12. reported simi-
lar findings in 2011; they developed TaqMan assay (Applied 
Biosystems, Carlsbad, CA) with peptide nucleic acid (PNA) 
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clamping (0.02% sensitivity) to assess T790M mutation in 
two cohorts of NSCLCs with sensitive EGFR mutations and 
found the T790M mutation rates to be 35% (45 of 129) and 
38% (30 of 78), respectively. No validation of the results 
using a second sensitive method was included. Moreover, in 
2008, Maheswaran’s14 group reported that 10 of 26 NSCLCs 
(38%) with sensitive EGFR mutations contained low levels 
of T790M mutation in the pre-TKI specimens. They used 
Scorpion Amplification Refractory Mutation System (DxS, 
Qiagen, Manchester, UK) for T790M detection and identified 
as few as one T790M mutation in 500 EGFR alleles (using 
cloning and sequencing; 0.2% sensitivity). However, impor-
tantly, other groups analyzing similar sample sets using the 
same method have not reported these frequencies of T790M 
mutations.15,16 In summary, all three groups, by using highly 
sensitive assays (3.71%–0.02% sensitivity), identified approx-
imately 40% T790M-positive rate in TKI-naive NSCLCs with 
sensitive EGFR mutations. If this is true, with T790M being 
detected in NSCLCs before TKI, it would help tremendously 
in the trial design and in the optimization of treatment strate-
gies to maximize their efficacious benefits. In addition, the 
presence of high frequency of T790M in pre-TKI NSCLCs 
would prompt the first-line application of second-generation 
TKIs, which might benefit in delaying or preventing the TKI 
resistance.
However, when we looked into the sample information 
of these reports, we realized that all three groups had used 
formalin-fixed samples for T790M detection and in some 
cases the developed assays had not been validated on the 
FFPE material they were being used on, but rather unfixed 
cell lines. This raised a concern that the high T790M posi-
tivity could be a consequence of formalin fixation, as there 
were reports showing that artificial gene mutations could be 
detected from formalin-fixed sample when using sensitive 
methods and insufficient assay validation.17–19 To address 
this concern, we collected 36 TKI-naive NSCLC tumor tis-
sue samples carrying sensitive EGFR mutations, including 
19-Del (13 of 36; 36%), L858R (18 of 36; 50%) and other 
mutations (5 of 36; 14%), and their adjacent normal lung tis-
sue samples when available, in both frozen and FFPE formats. 
Deoxyribonucleic acids (DNA) from frozen and FFPE speci-
mens were extracted by Puregene DNA extraction kit (Cat. 
#: 158388; Qiagen, Germantown, MD) and QIAamp DNA 
FFPE Tissue Kit (Cat. #: 56404; Qiagen, Hilden, Germany), 
respectively. T790M was detected using an enzyme-based 
ME-PCR assay with 0.1% sensitivity according to a previous 
report with some modifications.3 All samples were tested in 
duplicate with 50 ng DNA input per reaction.
When the cases positive in both singleton and duplicate 
were counted, a T790M-positive rate of 41.7% (15 of 36) in the 
tumor FFPE samples was detected, which was similar to that 
in previous reports. However, only one of the 36 frozen coun-
terparts (2.8%) was T790M positive, which showed positive 
in duplicate and was validated by standard Sanger sequenc-
ing (the tumor FFPE sample from this patient was also posi-
tive in duplicate, although the adjacent normal FFPE sample 
was positive in singleton). Surprisingly, 48.5% (16 of 33) of 
T790M-positive rate was identified in the adjacent normal 
FFPE tissues as well whereas none of the 35 adjacent normal 
frozen tissues was T790M positive (3 normal FFPE samples 
and 1 normal frozen sample were not available for detection). 
If only the cases positive in duplicate were taken into consid-
eration, about 20% of T790M-positive rate would have been 
detected in both tumor and adjacent normal FFPE samples. 
Our results (summarized in Table 1), for the first time, sug-
gested that the high T790M positivity detected in TKI-naive 
NSCLCs using highly sensitive methods may actually be the 
FFPE-derived artifacts.
It was reported that formalin fixation could lead to 
false-positive somatic mutations although most, if not all 
of these artifacts can be distinguished from true mutations 
by performing duplicate sequencing from the original DNA 
sample.20 In this study, however, duplicate analysis would 
not have resolved the issue because of the frequency of the 
artifacts in T790M locus generated by this assay on FFPE 
material. Williams et al.17 reported that a high frequency of 
sequence alterations was detected in formalin-fixed samples 
but not in frozen samples. Moreover, 96% (27 of 28) of the 
artificial mutations were C-T or G-A transitions, which hap-
pened to be the mutation type of T790M. Similarly, Quach 
et al.18 also reported significantly more mutations from 
formalin-fixed samples than from the corresponding fro-
zen samples, among which 92% were transition mutations 
(C-T or G-A). The study by Inukai et al.3,21 supported the 
false-positive detection of T790M in FFPE samples. The 
authors identified 4% (4 of 95) of T790M mutation rate 
using the highly sensitive ME-PCR assay (0.1% sensitiv-
ity) in TKI-naive NSCLCs with sensitive EGFR mutations. 
These 95 samples positive for sensitive EGFR mutations 
were from 280 clinical specimens of different formats, with 
TABLE 1. EGFR-T790M Mutation Detection by Mutant-Enriched Polymerase Chain Reaction
FFPE Samples Paired Frozen Samples
Tumor Adjacent Normal Tumor Adjacent Normal
Total number of cases. 36 33 36 35
T790M
Positive in singleton/duplicatea 15 (41.7%) 16 (48.5%) 1 (2.8%) 0
Positive in duplicateb 7 (19.4%) 7 (21.2%) 1 (2.8%) 0
aIncluding the cases positive in only one singleton reaction and the cases positive in duplicate reactions.
bIncluding only the cases positive in duplicate reactions.
EGFR, epidermal growth factor receptor; FFPE, formalin-fixed paraffin-embedded.
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approximately 80% frozen specimens, approximately10% 
formalin-fixed specimens, and approximately 10% pleu-
ral fluid. Although there is no information regarding the 
EGFR mutation status versus sample format of individual 
samples, the fact that majority of samples were frozen type 
might explain the much lower T790M rate (4% versus ~40% 
reported before) detected in this cohort of samples with 
comparably sensitive assay applied.
Previous studies9,10 suggested that direct DNA 
sequencing was able to detect T790M in approximately 2% 
of pre-TKI NSCLC patients carrying sensitive EGFR muta-
tions. Our study here using highly sensitive assay (0.1% sen-
sitivity) also detected 2.8% T790M rate in frozen pre-TKI 
NSCLC patients. It indicates that with as high as 0.1% detec-
tion sensitivity, only about 2% of pre-TKI NSCLCs carry 
T790M mutation. However, it remains a question whether 
higher authentic T790M rate could be detected from pre-
treatment NSCLC if a more sensitive method is applied. 
A recent study by Fujita et al.22 reported 79% positive rate 
of T790M among totally 38 frozen samples of pre-TKI 
NSCLCs carrying sensitive EGFR mutations. They used 
colony-hybridization technique, which was claimed to have 
0.01% sensitivity. However, additional studies are needed to 
include more frozen tumor samples and different technical 
platforms are required to confirm this.
In conclusion, care should be taken when analyzing 
FFPE material to significantly reduce or eliminate artificial 
errors. Tests should be validated on the material they are 
intended to be used on, and at least a proportion of the results 
should be confirmed by an alternative method. Duplicate or 
repeat analysis should be considered as a means of reducing 
the chance of error so that sensitive test results on FFPE are 
reliable.
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